Manisa Celal Bayar University, Department of Otorhinolaryngology, Manisa Turkey.
Department of Otorhinolaryngology, İzmir Katip Çelebi University, Ataturk Training and Research Hospital, İzmir, Turkey.
J Int Adv Otol. 2020 Apr;16(1):28-33. doi: 10.5152/iao.2019.6522.
The aim of the present study was to determine the efficacy of propranolol treatment in patients with vestibular migraine by the Visual Analog Scale, Dizziness Handicap Inventory (DHI), Vertigo Symptom Scale, and Vestibular Disorders Activities of Daily Living Scale (VADL) and its effect on the quality of life.
The study population consisted of 38 patients with vertigo/dizziness who underwent routine evaluation and vestibular examinations, were diagnosed with definitive vestibular migraine, and received the same medical treatment protocol (propranolol). The questionnaires and scales that were applied to the patients before and after treatment were evaluated. The results were evaluated with 95% confidence interval, and p<0.05 was accepted as statistically significant.
The mean age of the patients was 47.55 (18-75) years, and 27 (71%) patients were female, and 11 (29%) were male. The mean total scores of the DHI before and after treatment were 50.21±22.39 (range: 8-92) and 9.31±9.86 (range: 0-58), respectively (p<0.001). The degree of disability after treatment was low in all patients (p<0.001). The total scores of the VADL before and after treatment were 186.63±79.65 (range: 32-280) and 55.52±51.89 (range: 28-273), respectively (p<0.001). There was no correlation between these two scales (p=0.235).
To our knowledge, this is the first study to evaluate both the efficacy of propranolol treatment and its effects on the quality of life in vestibular migraine. The severity, frequency, and number of attacks and disability scores were reduced, and the quality of life was improved in patients with vestibular migraine with propranolol treatment.
本研究旨在通过视觉模拟量表、眩晕残障程度评定量表（DHI）、眩晕症状量表和前庭疾病日常生活能力量表（VADL）评估普萘洛尔治疗前庭性偏头痛患者的疗效，并探讨其对生活质量的影响。
本研究共纳入 38 例眩晕/头晕患者，所有患者均接受常规评估和前庭检查，确诊为明确的前庭性偏头痛，并接受相同的药物治疗方案（普萘洛尔）。在治疗前后对患者进行问卷调查和量表评估。结果采用 95%置信区间表示，以 p<0.05 为差异有统计学意义。
患者的平均年龄为 47.55（18-75）岁，其中 27 例（71%）为女性，11 例（29%）为男性。治疗前后 DHI 总评分分别为 50.21±22.39（8-92）和 9.31±9.86（0-58），差异有统计学意义（p<0.001）。所有患者治疗后的残疾程度均较低（p<0.001）。治疗前后 VADL 总评分分别为 186.63±79.65（32-280）和 55.52±51.89（28-273），差异有统计学意义（p<0.001）。这两个量表之间无相关性（p=0.235）。
据我们所知，这是首个评估普萘洛尔治疗前庭性偏头痛的疗效及其对生活质量影响的研究。普萘洛尔治疗可降低前庭性偏头痛患者的严重程度、发作频率、发作次数和残疾评分，提高其生活质量。
